Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Anagrelide Hydrochloride

FDA-approved product (capsule, oral), marketed as Agrylin, Anagrelide Hydrochloride.

Registered studies
28
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Anagrelide Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Essential thrombocythemia
  • Myeloproliferative disorder
  • Neoplasm
  • Recurrent thrombophlebitis
  • Thrombotic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

28registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Anagrelide Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Anagrelide Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

    NCT06079879 · start 2023-12-31

    Registered record
    Registry ID
    NCT06079879
    Conditions
    Essential Thrombocythemia
    Interventions
    Bomedemstat; Anagrelide; Busulfan; Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-12-31
    Completion
    2028-08-18
    Enrolment
    340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia
    InterventionBomedemstat; Anagrelide; Busulfan; Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

    NCT04562870 · start 2021-03-17

    Registered record
    Registry ID
    NCT04562870
    Conditions
    Myelofibrosis
    Interventions
    Selinexor; Physician's Choice Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-03-17
    Completion
    2026-09
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis
    InterventionSelinexor; Physician's Choice Treatment
    PhasePhase 2
    Registry statusActive not recruiting

  • Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

    NCT04285086 · start 2020-08-25

    Registered record
    Registry ID
    NCT04285086
    Conditions
    Essential Thrombocythemia
    Interventions
    Ropeginterferon alfa-2b; Anagrelide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-08-25
    Completion
    2029-08-31
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia
    InterventionRopeginterferon alfa-2b; Anagrelide
    PhasePhase 3
    Registry statusActive not recruiting

  • Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

    NCT03866434 · start 2019-02-26

    Registered record
    Registry ID
    NCT03866434
    Conditions
    Healthy Volunteers
    Interventions
    SPD422; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-02-26
    Completion
    2019-04-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionSPD422; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

    NCT03123588 · start 2017-11-14

    Registered record
    Registry ID
    NCT03123588
    Conditions
    MPN (Myeloproliferative Neoplasms)
    Interventions
    Ruxolitinib; Anagrelide; Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-11-14
    Completion
    2020-08-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMPN (Myeloproliferative Neoplasms)
    InterventionRuxolitinib; Anagrelide; Placebo; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

    NCT03232177 · start 2017-06-05

    Registered record
    Registry ID
    NCT03232177
    Conditions
    Essential Thrombocythemia
    Interventions
    Anagre Cap.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-06-05
    Completion
    2020-12-05
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia
    InterventionAnagre Cap.
    PhasePhase 4
    Registry statusCompleted

  • The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

    NCT02962388 · start 2017-01-03

    Registered record
    Registry ID
    NCT02962388
    Conditions
    Essential Thrombocythemia
    Interventions
    Anagrelide; Ruxolitinib (JAKAVI®); IFNα/ PegIFNα
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2017-01-03
    Completion
    2021-06-28
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia
    InterventionAnagrelide; Ruxolitinib (JAKAVI®); IFNα/ PegIFNα
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

    NCT02577926 · start 2015-10

    Registered record
    Registry ID
    NCT02577926
    Conditions
    Polycythemia Vera (PV); Essential Thrombocythemia (ET)
    Interventions
    Ruxolitinib; BAT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-10
    Completion
    2028-12
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia Vera (PV); Essential Thrombocythemia (ET)
    InterventionRuxolitinib; BAT
    PhasePhase 2
    Registry statusActive not recruiting

  • Agrylin Drug Use-Result Survey

    NCT03625895 · start 2014-11-25

    Registered record
    Registry ID
    NCT03625895
    Conditions
    Essential Thrombocythemia (ET)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-11-25
    Completion
    2021-03-11
    Enrolment
    1,826

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia (ET)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

    NCT02252159 · start 2014-07-31

    Registered record
    Registry ID
    NCT02252159
    Conditions
    MPN (Myeloproliferative Neoplasms)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-07-31
    Completion
    2019-08-03
    Enrolment
    2,544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMPN (Myeloproliferative Neoplasms)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

    NCT02101268 · start 2014-06-19

    Registered record
    Registry ID
    NCT02101268
    Conditions
    Primary Myelofibrosis (PMF); Post-polycythemia Vera (Post-PV); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
    Interventions
    Momelotinib; Best Available Therapy (BAT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-19
    Completion
    2019-04-25
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Myelofibrosis (PMF); Post-polycythemia Vera (Post-PV); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
    InterventionMomelotinib; Best Available Therapy (BAT)
    PhasePhase 3
    Registry statusCompleted

  • A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

    NCT02125318 · start 2014-05

    Registered record
    Registry ID
    NCT02125318
    Conditions
    Thrombocytosis; Myeloproliferative Neoplasms
    Interventions
    Anagrelide CR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2016-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytosis; Myeloproliferative Neoplasms
    InterventionAnagrelide CR
    PhasePhase 2
    Registry statusCompleted

  • Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

    NCT02038036 · start 2014-03-25

    Registered record
    Registry ID
    NCT02038036
    Conditions
    Polycythemia Vera
    Interventions
    Best Available Therapy; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03-25
    Completion
    2020-04-07
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia Vera
    InterventionBest Available Therapy; Ruxolitinib
    PhasePhase 3
    Registry statusCompleted

  • Anagrelide Retard in Essential Thrombocythemia

    NCT02076815 · start 2014-02

    Registered record
    Registry ID
    NCT02076815
    Conditions
    Essential Thrombocythemia
    Interventions
    Anagrelide retard; Thromboreductin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2015-04
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Thrombocythemia
    InterventionAnagrelide retard; Thromboreductin
    PhasePhase 3
    Registry statusCompleted

  • HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

    NCT01668173 · start 2012-08

    Registered record
    Registry ID
    NCT01668173
    Conditions
    Myeloproliferative Neoplasms
    Interventions
    AUY922
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-08
    Completion
    2015-05
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeloproliferative Neoplasms
    InterventionAUY922
    PhasePhase 2
    Registry statusTerminated